Clinical Trial Update: Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of SOT102 antibody-drug conjugate in advanced gastric and pancreatic adenocarcinoma has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• SOT102

Snippet

Sponsor: SOTIO Biotech a.s. | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-11-17